GSK cuts 1,217 jobs in Belgium; unions decry profit-driven restructuring

GSK announced 1,217 job cuts in Belgium, which Solidaris and Setca denounce as a consequence of prioritizing superprofits over productive activity, citing 2.4 billion euros in net profits for GSK Biologicals in 2025 and public aid. The restructuring signals a shift in GSK's investment toward high-margin treatments, raising concerns about vaccine production and local economic impact. The decision is confirmed but its broader implications for GSK's operations remain uncertain.